About AKESO Company

Kangfang Biotechnology (Cayman) Co., Ltd. is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs that are affordable to patients around the world. Since its establishment, the company has established an end-to-end comprehensive drug development platform (ACE platform), covering fully integrated drug discovery and development functions, including target verification, antibody drug discovery and development, CMC production process development, and production in line with GMP standards. The company has also successfully developed bispecific antibody drug development technology (Tetrabody technology), which helps us overcome the three CMC problems encountered in the development and production of bispecific antibodies, including inefficient expression levels, process development barriers, and antibody stability and pharmacogenicity. The company currently has more than 50 research and innovation projects, covering the fields of oncology, autoimmune and metabolic diseases. Nineteen are in clinical trials (including 31 commercialized products and 42 externally authorized products), of which 6 are potential first-in-class (first-in-class) or best-in-class (best-in-class) bispecific antibodies. The company hopes to become the world's leading biopharmaceutical company by developing new drugs with the first of its kind or best-in-class treatments through efficient and innovative research and development.